AgingResearch.NewsJoin free

COVID-19 mRNA vaccine

COVID-19 mRNA vaccine has been studied in 3 papers since 2022: 1 observational study in people, 1 in animals, 1 review. The newest paper, Jan 19, 2023: “COVID-19 mRNA Vaccine Effectiveness against Elderly Frail People”.

Intervention

3 papers study it1 findingUpdated

“The 3rd mRNA dose elicited a 99-fold relative increase of S-binding IgG in blood and corresponding increase of neutralizing antibodies.”
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational studyThe Lancet regional health. Europe2023doi:10.1016/j.lanepe.2023.100646

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Familjen Erling-Perssons Stiftelse and 8 more
  • Humans1
  • Animals1

What did studies of COVID-19 mRNA vaccine find?

1

Studies of COVID-19 mRNA vaccine measured 1 outcome; the most studied are S-binding IgG (1 study).

S-binding IgG

upin humans1

1 study

  1. COVID-19 mRNA vaccine increases S-binding IgG in humans (99-fold).

    “The 3rd mRNA dose elicited a 99-fold relative increase of S-binding IgG in blood and corresponding increase of neutralizing antibodies.”

    Humansmonovalent3rd dose

    Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study

    The Lancet regional health. Europe

More on S-binding IgG

Latest

Related